Clinical Trial Update: Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial evaluating G1X-CGD, a lentiviral vector–transduced CD34+ cell therapy for X-linked Chronic Granulomatous Disease, currently enr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• G1X-CGD

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Chronic Granulomatous Disease (CGD) | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION